BioCentury | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

...on the HSV and adenovirus backbones. Companies with HSV therapies include Replimune, Oncorus Inc. and Virogen...
BioCentury | Sep 25, 2008
Distillery Therapeutics

This Week in Therapeutics

...compounds in mouse models of type 2 diabetes. Celgosivir (MX-3253), an a-glucosidase I inhibitor from Virogen Ltd....
...II testing to treat chronic HCV infection. Migenix Inc. has global rights to celgosivir from Virogen...
BioCentury | Jun 2, 2008
Company News

Migenix infectious, dermatology news

...the trial next quarter. Migenix acquired global rights to the alpha glucosidase I inhibitor from Virogen Ltd....
BioCentury | Feb 4, 2008
Clinical News

Celgosivir: Expand Phase II

...acquired global rights to celgosivir from Virogen in 2004. Migenix Inc. (TSX:MGI; Pink:MGIFF), Vancouver, B.C. Virogen Ltd....
BioCentury | Feb 9, 2004
Company News

Micrologix, Virogen deal

...MBI acquired global rights to Virogen's celgosivir, an oral antiviral in Phase I/II testing to treat...
...I/II testing to treat chronic HCV. MBI plans to start Phase II testing this year. Virogen...
...equity, and is eligible for milestones and royalties. Micrologix Biotech Inc. (TSE:MBI; MGIXF), Vancouver, B.C. Virogen Ltd....
BioCentury | Mar 5, 2001
Company News

Virogen, Aventis deal

...inhibitor that has completed Phase I/II testing to treat viral hepatitis (see BioCentury, Jan. 22). Virogen Ltd....
BioCentury | Jan 22, 2001
Emerging Company Profile

Corporate Profile

Virogen Drug Discovery Ltd. London, U.K. Technology: Small molecule drug discovery for antivirals Disease focus: Chronic and acute viral disease Clinical status: Preclinical Founded: 1999 by Stan Tyms, Debra Taylor and David Copsey Corporate partners:...
BioCentury | Jan 22, 2001
Emerging Company Profile

Virogen: MRC's antiviral play

...interested in working on viruses. In essence, according to Stan Tyms, president and CEO of Virogen...
...from tech transfer toward incubation of new companies and the result was the formation of Virogen...
...own. Virogen also hopes to expand its in-house glycoprotein processing expertise by adding medicinal chemistry. Virogen's...
BioCentury | Dec 4, 2000
Company News

Arrow Therapeutics, Virogen deal

...develop therapeutics to treat respiratory syncytial virus (RSV). Arrow will provide its compound library to Virogen...
...fund its own development costs, and revenues will be shared. Arrow Therapeutics Ltd., London, U.K. Virogen Ltd....
BioCentury | Dec 1, 2000
Company News

Arrow in RSV deal with Virogen

...Arrow Therapeutics (London, U.K.) and Virogen (London, U.K.) will develop therapeutics to treat respiratory syncytial virus...
...develop therapeutics to treat respiratory syncytial virus (RSV). Arrow will provide its compound library to Virogen...
Items per page:
1 - 10 of 10
BioCentury | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

...on the HSV and adenovirus backbones. Companies with HSV therapies include Replimune, Oncorus Inc. and Virogen...
BioCentury | Sep 25, 2008
Distillery Therapeutics

This Week in Therapeutics

...compounds in mouse models of type 2 diabetes. Celgosivir (MX-3253), an a-glucosidase I inhibitor from Virogen Ltd....
...II testing to treat chronic HCV infection. Migenix Inc. has global rights to celgosivir from Virogen...
BioCentury | Jun 2, 2008
Company News

Migenix infectious, dermatology news

...the trial next quarter. Migenix acquired global rights to the alpha glucosidase I inhibitor from Virogen Ltd....
BioCentury | Feb 4, 2008
Clinical News

Celgosivir: Expand Phase II

...acquired global rights to celgosivir from Virogen in 2004. Migenix Inc. (TSX:MGI; Pink:MGIFF), Vancouver, B.C. Virogen Ltd....
BioCentury | Feb 9, 2004
Company News

Micrologix, Virogen deal

...MBI acquired global rights to Virogen's celgosivir, an oral antiviral in Phase I/II testing to treat...
...I/II testing to treat chronic HCV. MBI plans to start Phase II testing this year. Virogen...
...equity, and is eligible for milestones and royalties. Micrologix Biotech Inc. (TSE:MBI; MGIXF), Vancouver, B.C. Virogen Ltd....
BioCentury | Mar 5, 2001
Company News

Virogen, Aventis deal

...inhibitor that has completed Phase I/II testing to treat viral hepatitis (see BioCentury, Jan. 22). Virogen Ltd....
BioCentury | Jan 22, 2001
Emerging Company Profile

Corporate Profile

Virogen Drug Discovery Ltd. London, U.K. Technology: Small molecule drug discovery for antivirals Disease focus: Chronic and acute viral disease Clinical status: Preclinical Founded: 1999 by Stan Tyms, Debra Taylor and David Copsey Corporate partners:...
BioCentury | Jan 22, 2001
Emerging Company Profile

Virogen: MRC's antiviral play

...interested in working on viruses. In essence, according to Stan Tyms, president and CEO of Virogen...
...from tech transfer toward incubation of new companies and the result was the formation of Virogen...
...own. Virogen also hopes to expand its in-house glycoprotein processing expertise by adding medicinal chemistry. Virogen's...
BioCentury | Dec 4, 2000
Company News

Arrow Therapeutics, Virogen deal

...develop therapeutics to treat respiratory syncytial virus (RSV). Arrow will provide its compound library to Virogen...
...fund its own development costs, and revenues will be shared. Arrow Therapeutics Ltd., London, U.K. Virogen Ltd....
BioCentury | Dec 1, 2000
Company News

Arrow in RSV deal with Virogen

...Arrow Therapeutics (London, U.K.) and Virogen (London, U.K.) will develop therapeutics to treat respiratory syncytial virus...
...develop therapeutics to treat respiratory syncytial virus (RSV). Arrow will provide its compound library to Virogen...
Items per page:
1 - 10 of 10